Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY26 results · Oct–Dec 2025
Bliss GVS Pharma reported revenue from operations of ₹218.25 crore (up 3.7% from Q3 FY25) and net profit of ₹24.78 crore (down 4.0% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 218.25 | 210.42 | +3.7% | 244.40 | −10.7% |
| Other income | 18.46 | 15.27 | +20.9% | 20.18 | −8.5% |
| Total income | 236.71 | 225.68 | +4.9% | 264.58 | −10.5% |
| Profit before tax | 40.90 | 36.42 | +12.3% | 40.63 | +0.6% |
| Net profit for the period | 24.78 | 25.80 | −4.0% | 28.59 | −13.3% |
| Attributable to shareholders of the company | 23.27 | 23.80 | −2.3% | 27.25 | −14.6% |
| EPS, basic (₹) | 2.20 | 2.27 | −3.1% | 2.58 | −14.7% |
| Net margin (%) | 11.4 | 12.3 | 11.7 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 164.68 | 179.59 | −8.3% | 190.23 | −13.4% |
| Other income | 10.23 | 11.66 | −12.2% | 25.84 | −60.4% |
| Total income | 174.91 | 191.25 | −8.5% | 216.07 | −19.0% |
| Profit before tax | 25.29 | 29.77 | −15.0% | 33.46 | −24.4% |
| Net profit for the period | 18.61 | 21.05 | −11.6% | 24.79 | −24.9% |
| EPS, basic (₹) | 1.76 | 2.00 | −12.0% | 2.35 | −25.1% |
| Net margin (%) | 11.3 | 11.7 | 13.0 |
Consolidated
- Filed with BSE
- 10 Feb 2026, 19:16 IST
- Board meeting
- 10 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2026, 19:16 IST
- Board meeting
- 10 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE